Thermo Fisher's diversified life sciences tools and CDMO platform is recovering from the bioprocessing destocking cycle, with PPD clinical research growth and analytical instruments demand stabilizing. Biotech funding normalization should reaccelerate the bioproduction segment. Margin discipline and capital allocation through tuck-in M&A support compounding. China life sciences exposure remains a near-term headwind.
Thesis reviewed May 29, 2026
Thermo Fisher Scientific Inc. is headquartered in United States, which is currently showing elevated risk signals.
🇺🇸United States82EXITView United States risk detail →🏥Healthcare33NEUTRAL| Ticker | Company | Score | Gap | Signal Δ | Action |
|---|---|---|---|---|---|
| CVS | CVS Health Corporation | 40 | +15% | ↓3% | AVOID |
| HCA | HCA Healthcare Inc. | 40 | +9% | ↓3% | EARLY |
| UNH | UnitedHealth Group Inc. | 37 | +16% | ↓3% | AVOID |
| TMO | Thermo Fisher Scientific Inc. | 37 | +11% | ↓3% | EARLY |
| CI | The Cigna Group | 37 | +9% | ↓3% | NEUTRAL |
| ELV | Elevance Health Inc. | 37 | +7% | ↓3% | NEUTRAL |
| TEVA | Teva Pharmaceutical Industries Ltd. | 37 | +9% | ↓3% | NEUTRAL |
Investors who hold TMO may also have indirect exposure through these country funds.
TMO Q1 bioproduction revenue returns to growth
PPD clinical research bookings outperform peers
Estimates · Yahoo Finance · Not audited figures
| Politician | Party | Type | Amount | Trade Date | Return |
|---|---|---|---|---|---|
| Michael RulliOH | Buy | $1k–$15k | Dec 12, 24 | ||
| Alan Armstrong | Buy | $1k–$15k | Mar 27, 26 | ||
| Dan NewhouseWA | Buy | $1k–$15k | Jul 10, 26 | ||
| Dwight EvansPA | D | Sell | $1k–$15k | May 7, 26 | |
| Julia LetlowLA | R | Buy | $1k–$15k | Oct 23, 24 | |
| Julia LetlowLA | R | Buy | $1k–$15k | Apr 28, 25 | |
| Julia LetlowLA | R | Buy | $1k–$15k | Jul 25, 25 | |
| Angus S King, Jr. | Sell | $1k–$15k | Jul 21, 25 | ||
| Markwayne Mullin | Buy | $15k–$50k | May 13, 25 | ||
| Markwayne Mullin | Sell | $50k–$100k | Apr 8, 25 | ||
| Josh GottheimerNJ | D | Buy | $1k–$15k | Sep 10, 24 | |
| John JamesMI | R | Buy | $1k–$15k | Sep 4, 24 | |
| John JamesMI | R | Buy | $1k–$15k | Mar 6, 24 |